Kim Elsink1, Joris M van Montfrans1, Mariëlle E van Gijn2, Maartje Blom3, P Martin van Hagen4, T W Kuijpers5, Geert W J Frederix6. 1. Department of Pediatric Immunology and Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands. 2. Department of Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands. 3. Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Internal Medicine/Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 6. Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands. Electronic address: G.W.J.Frederix@umcutrecht.nl.
Abstract
BACKGROUND: New, innovative, costly diagnostic methods for patients with primary immunodeficiencies (PID) demand upfront insight into their potential cost savings and added value for individual patients. As such, high quality, comparable economic evaluations are of utmost importance to enable informed decisions. The objective of this review was therefore to create an extensive overview of current costing studies and potential cost savings of early diagnosis in primary immunodeficiency disease. METHODS: A literature search in PubMed was conducted and studies involving any form of costing study in the field of PIDs were included. Of the included studies, study characteristics, cost parameters and benefits of early diagnosis were extracted and outlined in separate tables. RESULTS: Twenty two studies met the inclusion criteria and were included in the review. The papers were categorized according to their subject: neonatal screening for severe combined immunodeficiency (SCID), Ig replacement therapies and studies reporting on costs of general or specific PIDs. Within and between these groups variability in reported costing characteristics was observed. In studies that reported cost savings pre- and post-diagnosis, cost savings ranged from 6500 to 108,463 USD of total costs per patient. CONCLUSION: This literature review shows that, regardless of what aspect of PIDs has been studied, in nearly all cases early diagnosis reduces health care consumption and leads to better health outcomes for patients with PIDs. We found considerable variability in costing characteristics of economic evaluations of PID patients, which hampers the comparability of outcomes. More effort is needed to create uniformity and define cost parameters in economic evaluations in the field of PIDs, facilitating further prospective research to extensively assess the benefits of early diagnosis.
BACKGROUND: New, innovative, costly diagnostic methods for patients with primary immunodeficiencies (PID) demand upfront insight into their potential cost savings and added value for individual patients. As such, high quality, comparable economic evaluations are of utmost importance to enable informed decisions. The objective of this review was therefore to create an extensive overview of current costing studies and potential cost savings of early diagnosis in primary immunodeficiency disease. METHODS: A literature search in PubMed was conducted and studies involving any form of costing study in the field of PIDs were included. Of the included studies, study characteristics, cost parameters and benefits of early diagnosis were extracted and outlined in separate tables. RESULTS: Twenty two studies met the inclusion criteria and were included in the review. The papers were categorized according to their subject: neonatal screening for severe combined immunodeficiency (SCID), Ig replacement therapies and studies reporting on costs of general or specific PIDs. Within and between these groups variability in reported costing characteristics was observed. In studies that reported cost savings pre- and post-diagnosis, cost savings ranged from 6500 to 108,463 USD of total costs per patient. CONCLUSION: This literature review shows that, regardless of what aspect of PIDs has been studied, in nearly all cases early diagnosis reduces health care consumption and leads to better health outcomes for patients with PIDs. We found considerable variability in costing characteristics of economic evaluations of PID patients, which hampers the comparability of outcomes. More effort is needed to create uniformity and define cost parameters in economic evaluations in the field of PIDs, facilitating further prospective research to extensively assess the benefits of early diagnosis.
Authors: Kim Elsink; Manon M H Huibers; Iris H I M Hollink; Annet Simons; Evelien Zonneveld-Huijssoon; Lars T van der Veken; Helen L Leavis; Stefanie S V Henriet; Marcel van Deuren; Frank L van de Veerdonk; Judith Potjewijd; Dagmar Berghuis; Virgil A S H Dalm; Clementien L Vermont; Annick A J M van de Ven; Annechien J A Lambeck; Kristin M Abbott; P Martin van Hagen; Godelieve J de Bree; Taco W Kuijpers; Geert W J Frederix; Mariëlle E van Gijn; Joris M van Montfrans Journal: Front Immunol Date: 2021-12-21 Impact factor: 7.561
Authors: Julia Nordin; Leire Solís; Johan Prévot; Nizar Mahlaoui; Helen Chapel; Silvia Sánchez-Ramón; Adli Ali; John W Seymour; Martine Pergent Journal: Front Immunol Date: 2021-11-18 Impact factor: 7.561
Authors: Tariq Al Farsi; Khwater Ahmed; Jalila Alshekaili; Mahmood Al Kindi; Matthew Cook; Aliya Al-Hosni; Zainab Ansari; Iman Nasr; Nashat Al Sukaiti Journal: Front Immunol Date: 2022-04-06 Impact factor: 8.786
Authors: Helena M Cornelissen; Ernest M Musekwa; Richard H Glashoff; Monika Esser; Moleen Zunza; Deepthi R Abraham; Zivanai C Chapanduka Journal: Br J Haematol Date: 2022-07-06 Impact factor: 8.615
Authors: Lisanne M A Janssen; Kim van den Akker; Mohamed A Boussihmad; Esther de Vries Journal: Orphanet J Rare Dis Date: 2021-06-29 Impact factor: 4.123